Elsevier

Hearing Research

Volume 368, October 2018, Pages 28-40
Hearing Research

Review Article
Pharmacokinetic principles in the inner ear: Influence of drug properties on intratympanic applications

https://doi.org/10.1016/j.heares.2018.03.002Get rights and content

Highlights

  • Quantitative pharmacokinetic studies of the inner ear allow drug therapies to be compared.

  • Molecular properties determine how readily drugs pass through membranous boundaries of the ear.

  • The properties of dexamethasone-phosphate make it unsuitable as a therapy for hearing disorders.

Abstract

Local drug delivery to the ear has gained wide clinical acceptance, with the choice of drug and application protocol in humans largely empirically-derived. Here, we review the pharmacokinetics underlying local therapy of the ear using the drugs commonly used in clinical practice as examples. Based on molecular properties and perilymph measurements interpreted through computer simulations we now better understand the principles underlying entry and distribution of these and other drugs in the ear. From our analysis, we have determined that dexamethasone-phosphate, a pro-drug widely-used clinically, has molecular and pharmacokinetic properties that make it ill-suited for use as a local therapy for hearing disorders. This polar form of dexamethasone, used as a more soluble agent in intravenous preparations, passes less readily through lipid membranes, such as those of the epithelia restricting entry at the round window membrane and stapes. Once within the inner ear, dexamethasone-phosphate is cleaved to the active form, dexamethasone, which is less polar, passes more readily through lipid membranes of the blood-perilymph barrier and is rapidly eliminated from perilymph without distributing to apical cochlear regions. Dexamethasone-phosphate therefore provides only a brief exposure of the basal regions of the cochlea to active drug. Other steroids, such as triamcinolone-acetonide, exhibit pharmacokinetic properties more appropriate to the ear and merit more detailed consideration.

Introduction

It has been known for years that injecting a drug solution through the tympanic membrane into the middle ear allows the drug to reach and influence function of the inner ear (Ersner et al., 1951; Schuknecht, 1956). The field of local drug delivery to the ear took on greater relevance when in the mid-1990's local delivery of gentamicin became a widely-accepted clinical therapy for the treatment of Meniere's disease (Lange, 1989; Nedzelski et al., 1993; Toth and Parnes, 1995). Since that time, we have learned that the pharmacokinetics of the inner ear with locally-applied drugs is rather complex, involving the interaction of multiple elements. Some share similarities with other systems of the body, such as entry from the vasculature which has some similarities to that in the eye or the brain. Others, such as passage through the round window membrane, distribution through the different fluid and tissue compartments of the ear, and fluid exchange across the cochlear aqueduct, are unique to the ear. Here we review what we know so far about inner ear pharmacokinetics with a primary emphasis on drugs currently used in clinical practice.

The ear consists of a number of interconnected compartments that an applied drug can access.

  • 1)

    Middle ear. The middle ear is normally gas-filled but becomes a fluid-filled space communicating with perilymph when drug solution is applied there. The middle ear is lined with epithelium that on the ventral surface, leading to the Eustachian tube, is of endodermal origin and is densely ciliated. In contrast, dorsal surfaces of the epithelium and regions in the vicinity of the round window membrane and stapes are of neural crest origins and are not ciliated (Thompson and Tucker, 2013). The epithelium is both highly vascularized and includes lymphatic drainage to the retroauricular and junctional lymph nodes (Lim and Hussl, 1975). Fluid and/or drug loss through the Eustachian tube, via the vasculature and via the lymphatics can all contribute to the decline of middle ear concentration with time after drug application, as can fluid or mucus secretion by the epithelium. An initial breakdown (metabolism) of drugs in the middle ear also likely occurs but only limited quantitative data are yet available. The primary function of the middle ear epithelium is to maintain the normal gas-filled state and removal of applied drug solutions by these multiple processes occurs as a result of that specialization.

  • 2)

    Inner Ear. The inner ear comprises prominent fluid spaces containing endolymph or perilymph, but drugs entering the inner ear do not remain confined to just the fluid spaces. Most of the adjacent tissue spaces are not bounded by tissues with tight junctions so drugs rapidly equilibrate with the extracellular spaces of the spiral ligament, the organ of Corti, the spiral ganglion and of the auditory and vestibular nerves. Depending on permeability properties, drugs may enter the intracellular compartments of these tissues or become membrane-bound if lipophilic. Distribution between endolymph and perilymph depends on where the drug enters the ear, whether by systemic or local application, and whether the drug can pass through the tight, cellular endolymph-perilymph barrier. In the cochlea, distribution of charged molecules between endolymph and perilymph is also influenced by the endocochlear potential. Fluid spaces in the bone of the otic capsule also interact with perilymph, with incomplete bone-lining cells (Chole and Tinling, 1994) and a lacuno-canalicular system in the bone in open fluid communication with perilymph (Zehnder et al., 2005).

  • 3)

    Cranium. Perilymph is in open fluid communication with cerebrospinal fluid (CSF). The endolymphatic sac also contacts the dura mater in the posterior fossa. These communications raise the possibility that substances applied to perilymph may gain access to the brain. In rodents, where the cochlear aqueduct is relatively large, passage of drugs through the aqueduct is largely mitigated by the high rate of CSF turnover. While the CSF may be providing a sink to which perilymphatic drugs are lost (Salt et al., 2015), drug accumulation in CSF is generally low. Although in humans the aqueduct is longer and narrower, there are instances of hearing loss after intrathecal administration of ototoxic drug (Maarup et al., 2015). The passage of drugs from the ear to the brain via the auditory and vestibular nerves has also been proposed (Praetorius et al., 2007; Zhang et al., 2012).

  • 4)

    Vasculature. For the inner ear the vasculature represents a large sink to which drugs can be lost (or gained following systemic applications), impeded by the tight blood labyrinth barriers. This includes the blood-perilymph and blood-strial barriers which may have different characteristics. Each of the tissues of the middle and inner ear, including the bone of the otic capsule, has an associated vasculature that may contribute to the overall pharmacokinetics of the inner ear. It should also be borne in mind that any barrier is only as good as its weakest segment, with pharmacokinetics potentially influenced by local defects in the barrier.

A schematic of the main processes and compartments underlying inner ear pharmacokinetics with intratympanic drug applications is shown in Fig. 1. The figure shows a drug-containing formulation injected through the tympanic membrane into the middle ear cavity. Drug enters the inner ear through multiple pathways, including through the round window (RW) membrane and the stapes (King et al., 2011; Salt et al., 2012a). Drug is lost from the middle ear by multiple mechanisms, as discussed above. As the drug enters perilymph it initially distributes throughout the fluid and tissue spaces of basal turn and vestibule, with spread along the scalae towards the cochlear apex occurring more slowly. In the basal turn of ST, drug levels are diluted by CSF, either entering through the cochlear aqueduct as a volume flow, or as a CSF-perilymph exchange caused by pressure-induced fluid oscillations across the CA. Drug can be lost from the inner ear fluids by multiple processes, including uptake, buffering or binding to cellular or non-cellular components of the ear, or through elimination by the vasculature across the blood-labyrinth barriers.

Section snippets

Pharmacokinetics of the ear

Pharmacokinetics is the science of drug movements in the body, including absorption, distribution, metabolism, and excretion. In practice, however, all the applied drug may not be available so factors related to drug liberation are usually also considered, leading to the acronym LADME: Liberation, Absorption, Distribution, Metabolism and Elimination. In 2009, we first applied this concept to the ear (Salt and Plontke, 2009), providing a structured framework for systematically studying,

Molecular properties of drugs used in the ear

At present, only a small number of drugs are widely used in routine clinical practice for therapy of the ear. The aminoglycoside gentamicin is used to treat Meniere's disease (Lange, 1989; Nedzelski et al., 1993) and corticosteroids, mainly dexamethasone and methylprednisolone, are used to treat Meniere's disease, idiopathic sudden sensorineural hearing loss and other forms of acute hearing loss (Hamid and Trune, 2008). The different forms of these molecules that are used for therapy of the ear

Middle ear kinetics

When drug solution is injected into the middle ear it does not remain “undisturbed”, waiting for the dissolved drug to diffuse into the inner ear. As discussed earlier, the middle ear has a number of powerful mechanisms to remove fluids and drugs. For intratympanic applications in humans, the patient lies in a supine position for 20–30 min with the head orientated to keep the Eustachian tube uppermost, so that drug solution applied to the RW niche does not immediately drain towards the

Barriers of the ear

The main barriers to drug entry into the inner ear are formed by specialized cell layers, as reviewed elsewhere (Salt and Hirose, 2018). Endothelial cells of blood vessels provide the blood-perilymph and blood-strial barriers. They restrict the entry of systemically-applied drugs into the ear and control the elimination of locally-applied drugs. For drugs applied intratympanically, the primary barrier restricting passage into perilymph is the epithelium of the middle ear, which covers both the

Comparisons between drugs

The above analysis confirms that dexamethasone enters the ear far more readily than dexamethasone-phosphate, but can only be applied at low concentration due to its limited solubility. An important question is therefore which form of dexamethasone gives the highest perilymph concentration in absolute terms. The measured perilymph concentration, averaged across all 10 samples collected, was 2.18 μg/ml for dexamethasone (applied at a concentration of 94.2 μg/ml) and was 4.15 μg/ml for

Intratympanic applications

The amount and distribution of drug in perilymph depends both on the substance applied and on the application protocol. Based on the kinetic properties for the 3 drugs presented above we can calculate their likely distribution throughout the human inner ear for the application protocols typically used clinically, as shown in Fig. 8. This calculation assumes that pharmacokinetic properties derived from animal experiments are comparable to those in humans when scaled to the larger human ear. For

Conclusions and future directions

In the past decade, our capability to perform quantitative pharmacokinetic studies of the inner ear has improved dramatically. We now have fluid delivery and sampling techniques that have overcome serious technical artifacts that have plagued the field since its outset. We also have computer simulations of delivery and sampling procedures available for the ear that closely reproduce the measured data, allowing pharmacokinetic studies to be interpreted in detail in terms of amount and

Acknowledgement

Part of this work (ANS) was supported by the National Institute on Deafness and Other Communication Disorders (NIDCD) of the National Institutes of Health (NIH) under award number R01 DC001368. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

References (78)

  • A.N. Salt et al.

    Communication pathways to and from the inner ear and their contributions to drug delivery

    Hear. Res.

    (2018)
  • E.E. Swan et al.

    Inner ear drug delivery for auditory applications

    Adv. Drug Deliv. Rev.

    (2008)
  • Y.B. Zhang et al.

    Uptake of gentamicin by vestibular efferent neurons and superior olivary complex after transtympanic administration in Guinea pigs

    Hear. Res.

    (2012)
  • T.H. Alexander et al.

    Dose effect of intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss: 24 mg/mL is superior to 10 mg/mL

    Otol. Neurotol.

    (2015)
  • A.M. Ayoob et al.

    The role of intracochlear drug delivery devices in the management of inner ear disease

    Expet Opin. Drug Deliv.

    (2015)
  • P.A. Bird et al.

    Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph

    Otol. Neurotol.

    (2007)
  • R. Briggs et al.

    A first time in human investigation of a combination device delivering a targeted drug therapy to cochlear implant recipients

  • A. Daina et al.

    A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules

    ChemMedChem

    (2016)
  • A. Daina et al.

    SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

    Sci. Rep.

    (2017)
  • G. De Ceulaer et al.

    Long-term evaluation of the effect of intracochlear steroid deposition on electrode impedance in cochlear implant patients

    Otol. Neurotol.

    (2003)
  • D. Douchement et al.

    Dexamethasone eluting electrodes for cochlear implantation: effect on residual hearing

    Cochlear Implants Int.

    (2015)
  • W.J. Egan et al.

    Prediction of drug absorption using multivariate statistics

    J. Med. Chem.

    (2000)
  • M.S. Ersner et al.

    Transtympanic injection of anesthetics for the treatment of Ménière's syndrome

    AMA Arch Otolaryngol

    (1951)
  • F. Farahmand Ghavi et al.

    Corticosteroid-releasing cochlear implant: a novel hybrid of biomaterial and drug delivery system

    J. Biomed. Mater. Res. B Appl. Biomater.

    (2010)
  • L.N. Gillespie et al.

    Treating hearing disorders with cell and gene therapy

    J. Neural. Eng.

    (2014)
  • M.V. Goycoolea

    Clinical aspects of round window membrane permeability under normal and pathological conditions

    Acta Otolaryngol.

    (2001)
  • C. Grossmann et al.

    Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties

    Eur. J. Endocrinol.

    (2004)
  • H. Hahn et al.

    Dexamethasone levels and base-to-apex concentration gradients in the scala tympani perilymph after intracochlear delivery in the Guinea pig

    Otol. Neurotol.

    (2012)
  • M. Hamid et al.

    Issues, indications, and controversies regarding intratympanic steroid perfusion

    Curr. Opin. Otolaryngol. Head Neck Surg.

    (2008)
  • C. Honeder et al.

    Effects of intraoperatively applied glucocorticoid hydrogels on residual hearing and foreign body reaction in a Guinea pig model of cochlear implantation

    Acta Otolaryngol.

    (2015)
  • M. Jumaily et al.

    Intratympanic triamcinolone and dexamethasone in the treatment of Ménière's syndrome

    Otol. Neurotol.

    (2017)
  • A.M. Karssen et al.

    Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain

    Endocrinology

    (2001)
  • E.B. King et al.

    Direct entry of gadolinium into the vestibule following intratympanic applications in Guinea pigs and the influence of cochlear implantation

    J Assoc Res Otolaryngol

    (2011)
  • Š.1 Kordiš et al.

    The role of high dose intratympanic dexamethasone as salvage therapy for idiopathic sudden sensorineural hearing loss

    J Int Adv Otol

    (2017)
  • P.R. Lambert et al.

    Intratympanic sustained-exposure dexamethasone thermosensitive gel for symptoms of Ménière's disease: randomized phase 2b safety and efficacy trial

    Otol. Neurotol.

    (2016)
  • T.G. Landry et al.

    Chronic neurotrophin delivery promotes ectopic neurite growth from the spiral ganglion of deafened cochleae without compromising the spatial selectivity of cochlear implants

    J. Comp. Neurol.

    (2013)
  • G. Lange

    Gentamicin and other ototoxic antibiotics for the transtympanic treatment of Menière's disease

    Arch. Oto-Rhino-Laryngol.

    (1989)
  • E. Lecain et al.

    Steroidogenic enzyme expression in the rat cochlea

    Acta Otolaryngol.

    (2003)
  • D.J. Lim et al.

    Macromolecular transport by the middle ear and its lymphatic system

    Acta Otolaryngol.

    (1975)
  • Cited by (113)

    • Therapeutics for hearing preservation and improvement of patient outcomes in cochlear implantation—Progress and possibilities

      2022, Hearing Research
      Citation Excerpt :

      These differing membrane permeability characteristics present numerous challenges and considerations around the inner ear delivery approach chosen and the compound's retention. Different membrane permeability characteristics have also been reported for triamcinolone (poorer permeability) and triamcinolone acetonide (better permeability) as well as for methylprednisolone succinate (poorer permeability) and methylprednisolone (better permeability) (Salt and Plontke, 2018). As a result, the BOILED-Egg model assessment of other molecules in development is important to define their ability to readily cross membranous boundaries.

    • Potential nanotechnology-based diagnostic and therapeutic approaches for Meniere's disease

      2022, Nanomedicine: Nanotechnology, Biology, and Medicine
      Citation Excerpt :

      Another drug delivery approach is called direct microinjection, which improves a lack of control linked to IT injections, which may increase the risk of inner ear damage or trauma.120 Despite the use of techniques, several limitations exist associated with pharmacokinetics, and hence improved methods would improve drugs delivery for treatment of the inner ear.121,122 Emergence of NPs and their special properties in delivering various types of therapeutics has addressed many challenges of conventional drug delivery systems.123

    View all citing articles on Scopus
    View full text